Breast Cancer Research Continues...
Executive Summary
Phase III Study.. Adjuvant doxorubicin followed by cyclophosphamide/methotrexate/fluorouracil (CMF) vs. adjuvant doxorubicin/Taxol followed by CMF vs.primary doxorubicin/Taxol followed by CMF Enrollment....... 450 planned